首页> 外文期刊>Journal of Pharmacy and Pharmacology >Inhibitory effects of sertraline in rat isolated perfused kidneys and in isolated ring preparations of rat arteries.
【24h】

Inhibitory effects of sertraline in rat isolated perfused kidneys and in isolated ring preparations of rat arteries.

机译:舍曲林对大鼠离体灌注肾脏和离体大鼠动脉环制剂的抑制作用。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVES: Sertraline is often prescribed to patients suffering with end stage renal disease, but its action on kidney has not been investigated. We aimed to investigate the pharmacological action of sertraline on rat kidney with emphasis on the underlying mechanisms involved in the vascular actions of the drug. METHODS: The effects of sertraline were evaluated in rat isolated perfused kidneys and on ring preparations of mesenteric or segmental rat renal artery. KEY FINDINGS: In kidneys, sertraline prevented the effects of phenylephrine on perfusion pressure, glomerular filtration rate, urinary flow and renal vascular resistance. In mesenteric rings sertraline inhibited phenylephrine-induced contractions with potency 30-times lower than verapamil. Sertraline reversed sustained contractions induced by phenylephrine or 60mm K(+) within a similar concentration range. In segmental isolated rings, sertraline also reversed contractions induced by phenylephrine or 60mm K(+) with the same concentration range, but with higher potency compared with mesenteric preparations. Under Ca(2+) -free conditions, sertraline did not change the intracellularly-mediated phasic contractions induced by phenylephrine or caffeine. Sertraline was ineffective against contractions induced by extracellular Ca(2+) restoration after thapsigargin treatment and Ca(2+) store depletion with phenylephrine. Conversely, sertraline decreased the contractions induced by Ca(2+) addition in tissues under high K(+) solution or phenylephrine plus verapamil. CONCLUSIONS: In rat isolated kidneys and in rat ring preparations of mesenteric or renal vessels, sertraline had antispasmodic effects that appeared to be caused by a direct action on vascular smooth muscle cells. Its actions were ineffective against Ca(2+) -releasing intracellular pathways, but appeared to interfere with sarcolemmal Ca(2+) influx with reduced permeability of both receptor- and voltage-gated Ca(2+) channels.
机译:目的:舍曲林常用于患有终末期肾脏疾病的患者,但尚未研究其对肾脏的作用。我们旨在研究舍曲林对大鼠肾脏的药理作用,重点是与药物血管作用有关的潜在机制。方法:评价舍曲林对大鼠离体灌注肾脏和肠系膜或分段大鼠肾动脉环制剂的影响。主要发现:在肾脏中,舍曲林可防止去氧肾上腺素对血流灌注压,肾小球滤过率,尿流和肾血管阻力的影响。在肠系膜环中,舍曲林抑制苯肾上腺素引起的收缩,效力比维拉帕米低30倍。舍曲林扭转了苯肾上腺素或60mm K(+)在相似浓度范围内引起的持续收缩。在节段隔离的环中,舍曲林还可以逆转去氧肾上腺素或60mm K(+)引起的收缩,浓度范围相同,但与肠系膜制剂相比药效更高。在无Ca(2+)的条件下,舍曲林不会改变苯肾上腺素或咖啡因诱导的细胞内介导的相收缩。舍曲林对thapsigargin治疗和Ca(2+)存储与去氧肾上腺素耗尽后由细胞外Ca(2+)还原诱导的收缩无效。相反,舍曲林降低了在高K(+)溶液或去氧肾上腺素加维拉帕米下组织中Ca(2+)诱导的收缩。结论:在大鼠离体肾脏和肠系膜或肾脏血管的大鼠环制剂中,舍曲林具有镇痉作用,似乎是由对血管平滑肌细胞的直接作用引起的。它的作用对Ca(2+)释放细胞内途径无效,但似乎干扰了肌膜Ca(2+)的流入,同时降低了受体和电压门控Ca(2+)通道的通透性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号